- Home
- HOWL vs DXR Comparison
HOWL vs DXR Comparison
Compare HOWL & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- DXR
- Stock Information
- Founded
- HOWL 2017
- DXR 1970
- Country
- HOWL United States
- DXR United States
- Employees
- HOWL N/A
- DXR N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- DXR Medical/Dental Instruments
- Sector
- HOWL Health Care
- DXR Health Care
- Exchange
- HOWL Nasdaq
- DXR Nasdaq
- Market Cap
- HOWL 47.1M
- DXR 46.1M
- IPO Year
- HOWL 2021
- DXR N/A
- Fundamental
- Price
- HOWL $1.36
- DXR $10.14
- Analyst Decision
- HOWL Strong Buy
- DXR Strong Buy
- Analyst Count
- HOWL 3
- DXR 1
- Target Price
- HOWL $8.33
- DXR $25.00
- AVG Volume (30 Days)
- HOWL 554.2K
- DXR 3.3K
- Earning Date
- HOWL 08-07-2025
- DXR 01-01-0001
- Dividend Yield
- HOWL N/A
- DXR N/A
- EPS Growth
- HOWL N/A
- DXR 86.16
- EPS
- HOWL N/A
- DXR 0.11
- Revenue
- HOWL $1,143,000.00
- DXR $119,714.00
- Revenue This Year
- HOWL N/A
- DXR N/A
- Revenue Next Year
- HOWL N/A
- DXR N/A
- P/E Ratio
- HOWL N/A
- DXR $93.33
- Revenue Growth
- HOWL N/A
- DXR N/A
- 52 Week Low
- HOWL $0.60
- DXR $6.55
- 52 Week High
- HOWL $4.18
- DXR $10.14
- Technical
- Relative Strength Index (RSI)
- HOWL 60.96
- DXR 65.31
- Support Level
- HOWL $1.25
- DXR $9.05
- Resistance Level
- HOWL $1.44
- DXR $9.90
- Average True Range (ATR)
- HOWL 0.10
- DXR 0.29
- MACD
- HOWL 0.02
- DXR 0.02
- Stochastic Oscillator
- HOWL 68.89
- DXR 100.00
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.